Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.32 per share a year ago. These ...

Castle Biosciences, Inc. (CSTL) has been beaten down lately with too much selling pressure. While the stock has lost 16.8% over the past four weeks, there is light at the end of the tunnel as it is ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Castle Biosciences, Inc. (CSTL) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...

Castle Biosciences (CSTL) just got a meaningful vote of confidence, as an independent panel of melanoma experts published a consensus paper endorsing its DecisionDx Melanoma test as part of best ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds released “The RiverPark/Next Century Growth Fund” Q4 2023 investor letter in partnership with Next ...

Short interest in Castle Biosciences Inc (NASDAQ:CSTL) increased during the last reporting period, rising from 1.52M to 1.80M. This put 7.13% of the company's publicly available shares short. Short ...